MTOR and non-small cell lung carcinoma: These therapeutic efficacies were associated with the binding ability of FGFC1 to EGFRT790M/L858R and inactivation of PI3K/Akt/mTOR signaling pathway, which was important for driving tumorigenesis of NSCLC and TKI resistance.